Halozyme Therapeutics (HALO) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.39
- Estimate
- $2.36
- Surprise
- +1.5%
- Revenue (period 2026-09-30)
- $493.0M
- Score today
- 6.5/10
Revenue source: xbrl.
How the report landed
Halozyme Therapeutics (HALO) beat the $2.36 estimate with adjusted EPS of $2.39 — a modest 1.5% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates HALO Hold at 6.5/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +1.5% surprise compares with a -19.7% four-quarter average.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=9.1 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Analyst target reached - limited upside remaining
- Leverage penalty (D/E 15.2): -1.5
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $105.92
- Entry target
- $101.24
- Stop
- $94.15
The stock trades at 36.0× trailing but 11.5× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 28 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
HALO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $13.96B
- P/E (fwd)
- 11.5
- P/E (ttm)
- 36.0
- 52-week range
- $61.23–$134.00
- Off 52-week high
- 21.0%
- RSI (14)
- 28
- Volume vs avg
- 1.35×
- Score today
- 6.5/10